SU1691749A1 - Method for estimation of platelet aggregational activity - Google Patents

Abstract

The invention relates to medicine, namely to hemocoagulation, and can be used to assess the functional status of platelets. The aim of the invention is to increase the sensitivity of the method. For this, the platelet aggregation activity is determined by adding plasma to the platelet-rich plasma as an inducer of fibrin monomer aggregation followed by determining the time for the appearance of the aggregates.

Description

The invention relates to medicine, namely to hemocoagulation, and can be used to assess the functional status of platelets.

The aim of the invention is to increase the sensitivity of the method by using as an inducer in determining the aggregation activity of platelets fibrin monomer.

The method is carried out as follows.

Blood was taken with a low-impact, short needle with a wide lumen. A 1 mg stabilizer (3.8% sodium citrate solution) is poured into a siliconized tube, blood is drawn up to the 10 ml mark, and mixed with a stabilizer by gentle shaking. .2 OPN-8 (blood of patients with hematocrit over 0.55 l / l for 10 minutes at 1,500 rpm). Platelet-poor plasma is obtained by centrifuging platelet-rich plasma at 3000 rpm for 20 minutes in the same centrifuge.

Fibrin-monomer get by a known method.

A platelet-rich plasma of a sick and healthy person is taken (control), the platelet count per mm of each plasma is determined and the platelet count is made up to 150 thousand per mm3, using this plasma for its own poor platelet count. Then, 0.25 ml of plasma containing 150 thousand platelets per mm3 patient and healthy (control) are taken into glass tubes, placed in a water bath for 30 seconds at 37 ° C, 0.05 ml of soluble fibrin is added - monomer and measure when the tubes are rotated the time of appearance of the first aggregates (aggregation time) of platelets in the plasma of a sick and healthy person (control).

When accelerating the aggregation time in the patient's plasma compared with the control result is regarded as hyperagregation, and when the aggregation time lengthens

o you

xj n o

in the patient's plasma, in comparison with the control, is regarded as a decrease in aggregation.

Induction of platelet aggregation with soluble fibrin monomer is shown in Table 1.

Statistical data from a comparative analysis of the prototype method and other methods for investigating the function of platelets and the claimed method are shown in Table 2.

As can be seen from Table 2, the use of fibrin monomer as an inducer of aggregation reveals to a greater extent a change in the functional activity of platelets than the use of hemolysate-aggregation (prototype), especially in the group of patients with thrombocytopathy.

The proposed method examined 164 patients with various disorders in the hemostasis system, of which a decrease in aggregation time for soluble fibrin monomer was detected in 48 patients, hyperagregation with the same aggregation inducer was detected in 34 people.

PRI me R 1, Boln ZS, 34 years old, was admitted to the hospital for gastrointestinal bleeding. The examination of the hemostatic system revealed (see Table 1) a sharp decrease in the time of aggregation for soluble fibrin monomer (100 s in the patient, 30 s in the control). Aggregation on other inductors was within the normal range (ADP - 100%, thrombin-aggregation 95%, collagen-aggregation 100%, adrenaline-aggregation 105%).

PRI mme R 2. Bolna, A., 26 years. Diagnosis: phlebothrombosis of the lower extremities. A shortening of the aggregation time for soluble fibrin monomer (in

-

patient 15c. under control 30 s). Platelet aggregation to other inductors was increased (ADP aggregation 140%, thrombin aggregation 120%, adrenaline aggregation 135%,

5 collagen aggregation 130%).

Use of soluble fibrin monomer to evaluate platelet aggregation in patient Z.S. allowed to explain the cause of gastrointestinal bleeding,

10 normal aggregation into known inducers (ADP, thrombin, collagen, adrenaline) was markedly sharply reduced aggregation into soluble fibrin monomer. The second patient, GA. hyperaggregation was noted

15 platelets on known inducers of aggregation, as well as platelet hyperaggregation on soluble fibrin monomer, which made it possible to explain the propensity for blood clotting by fibrin clot20.

Thus, the use of the proposed solution makes it possible to evaluate the previously unstudied platelet aggregation function, which improves the accuracy of the diagnosis of disorders in the hemostasis system. The claimed method can be used in clinical diagnostic laboratories of various types of hospitals (including the central district hospital).

thirty

Claims (1)

The method of determining the platelet aggregation activity by adding an inducer of platelet aggregation to the platelet-rich plasma and determining the occurrence time of the aggregates, characterized in that, in order to increase the sensitivity of the method, fibrin monomer is used as an inducer of platelet aggregation. Table 1 Note. + - the presence of platelet aggregation. Table 2